Prothena Corporation PLC (NASDAQ:PRTA) insider Gene G. Kinney sold 2,800 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $196,000.00. Following the transaction, the insider now directly owns 5,593 shares of the company’s stock, valued at approximately $391,510. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) opened at 64.77 on Friday. Prothena Corporation PLC has a 1-year low of $40.58 and a 1-year high of $69.53. The stock’s market capitalization is $2.48 billion. The firm has a 50-day moving average price of $59.56 and a 200-day moving average price of $56.28.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The business had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. During the same period in the previous year, the business earned ($1.18) EPS. The business’s quarterly revenue was up 7951.1% on a year-over-year basis. On average, equities research analysts forecast that Prothena Corporation PLC will post ($4.39) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Gene G. Kinney Sells 2,800 Shares of Prothena Corporation PLC (PRTA) Stock” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/gene-g-kinney-sells-2800-shares-of-prothena-corporation-plc-prta-stock/1600801.html.

Several equities analysts have recently issued reports on the company. BidaskClub raised Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Jefferies Group LLC started coverage on Prothena Corporation PLC in a report on Monday, July 10th. They issued a “buy” rating and a $100.00 price objective for the company. ValuEngine upgraded Prothena Corporation PLC from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price target on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $79.00 price target on shares of Prothena Corporation PLC in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $78.58.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its stake in shares of Prothena Corporation PLC by 12.8% during the 1st quarter. Russell Investments Group Ltd. now owns 12,030 shares of the biotechnology company’s stock worth $671,000 after buying an additional 1,369 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Prothena Corporation PLC by 6.4% in the 1st quarter. Bank of New York Mellon Corp now owns 171,970 shares of the biotechnology company’s stock worth $9,594,000 after acquiring an additional 10,397 shares during the period. Swiss National Bank grew its holdings in shares of Prothena Corporation PLC by 31.2% in the 1st quarter. Swiss National Bank now owns 62,300 shares of the biotechnology company’s stock worth $3,476,000 after acquiring an additional 14,800 shares during the period. Karp Capital Management Corp acquired a new stake in shares of Prothena Corporation PLC in the 1st quarter worth approximately $243,000. Finally, Ameritas Investment Partners Inc. acquired a new stake in shares of Prothena Corporation PLC in the 1st quarter worth approximately $167,000.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.